Extended Data Table 1 Objective response rate by IMDC risk category

From: Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

  1. Objective response assessment in cabozantinib–nivolumab arm (n = 10) and cabozantinib–nivolumab plus CBM588 arm (n = 19) by IMDC risk category.